[CAS NO. 7578-25-8] Lacto-N-fucopentaose I
PRODUCTS SPECIFICATIONS [7578-25-8]
DESCRIPTION [7578-25-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 853.77 |
| Molecular Formula | C32H55NO25 |
| SMILES | CC(N[C@@H]1[C@H]([C@@H]([C@@H](CO)O[C@H]1O[C@]2([H])[C@H]([C@@H](O[C@H](CO)[C@@H]2O)O[C@@]([C@H](O)CO)([H])[C@H](O)[C@@H](O)C=O)O)O)O[C@@]3([H])[C@@H]([C@H]([C@@H](O)[C@@H](CO)O3)O)O[C@@]4([H])[C@H]([C@@H]([C@H](O)[C@H](C)O4)O)O)=O |
Summary
Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote CDK2 and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development [1] .
IC50 & Target
|
Human Endogenous Metabolite |
CDK2/cyclinE |
In Vitro
Lacto-N-fucopentaose I (25-3200 μg/mL;48 h) exhibits certain cytotoxicity at 3200 μg/mL but no toxic reaction below 1600 μg/mL
[1]
.
Lacto-N-fucopentaose I (25-1600 μg/mL; 14-18 h) can protect EV71-infected RD cells from death
[1]
.
Lacto-N-fucopentaose I (100-400 μg/mL; 16 h) decreases markedly mRNA levels of VP1 and ROS production in EV71-infected RD cells at 400 μg/mL; leads to the recovery of EV71-induced S phase arrest in RD cells
[1]
.
Lacto-N-fucopentaose I (100 and 200 μg/mL; 3 days) inhibits cell apoptosis in
Caenorhabditis elegans
; significantly decreases the levels of
Egl-1
,
Ced-3
and
Ced-4
[1]
.
Lacto-N-fucopentaose I can reduce the abundance of
Sphingobacterium
,
Stenotrophomonas
and
Achromobacter
; can increase the abundance of
Micromonospora
,
Vibrio
,
Acidibacter
,
Gaiella
,
Devosia
,
Steroidobacter
,
Variibacter
,
Dactylosporangium
,
RB41
,
Pir4_lineage
,
Pirellula
,
Haliangium
,
Roseiflexus
,
Pedomicrobium
, and
Bradyrhizobium
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | RD cells |
| Concentration: | 25, 50, 100, 200, 400, 800, 1600 and 3200 μg/mL |
| Incubation Time: | 48 h |
| Result: | Exhibited certain cytotoxicity at 3200 μg/mL but no toxic reaction below 1600 μg/mL. |
RT-PCR [1]
| Cell Line: | RD cells (infected with EV71) |
| Concentration: | 100, 200 and 400 μg/mL |
| Incubation Time: | 16 h |
| Result: | Decreased markedly mRNA levels of VP1 only at 400 μg/mL. |
Apoptosis Analysis [1]
| Cell Line: | RD cells (infected with EV71) |
| Concentration: | 100, 200 and 400 μg/mL |
| Incubation Time: | 16 h |
| Result: |
Decreased the rate of cells in early apoptosis to 10.9% ± 1.26% at 400 μg/mL, while the untreated EV71 group was 27.7% ± 2.13%.
Significantly inhibited the activity of caspase-3, caspase-8 and caspase-9. Recovered the decreased mRNA expression of PAPR, NF-κB and Bcl-2 and properly regulated Bad and Fas into their normal levels. |
Cell Cycle Analysis [1]
| Cell Line: | RD cells (infected with EV71) |
| Concentration: | 100, 200 and 400 μg/mL |
| Incubation Time: | 12 h |
| Result: | Rescued EV71-induced S phase arrest, which promoted the transition of the G1 phase to the S phase. |
Appearance
Solid
Source
human milk
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)